C57BL/6JCya-Cdkn2aem1flox/Cya
Common Name
Cdkn2a-flox
Product ID
S-CKO-01681
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-12578-Cdkn2a-B6J-VA
When using this mouse strain in a publication, please cite “Cdkn2a-flox Mouse (Catalog S-CKO-01681) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Cdkn2a-flox
Strain ID
CKOCMP-12578-Cdkn2a-B6J-VA
Gene Name
Product ID
S-CKO-01681
Gene Alias
Arf, p16, MTS1, Pctr1, p19ARF, p16INK4a, p19<ARF>, ARF-INK4a, INK4a-ARF, Ink4a/Arf, p16(INK4a)
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 4
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000060501
NCBI RefSeq
NM_001040654
Target Region
Exon 1
Size of Effective Region
~1.5 kb
Overview of Gene Research
Cdkn2a, encoding p16 and p14, is a crucial tumor suppressor gene [1,2]. It is involved in cell cycle regulation, as p16 inhibits CDK4/6, thus controlling cell proliferation. Its loss is linked to tumor progression, making it of great biological importance in cancer research [1].
Loss of Cdkn2a is a frequent driver of melanoma progression. Pharmacological inhibition of p16 targets CDK4/6, which is a potential therapeutic strategy. Other approaches include exploiting cell cycle deregulation, targeting metabolic rewiring, epigenetically restoring expression, acting on co-deleted gene dependencies, or modulating immune responses [1]. Additionally, CDKN2A is the most common homozygously deleted gene in all human cancers. Tumors often codelete the nearby gene MTAP, creating a dependency on PRMT5, and MTA-cooperative PRMT5 inhibitors show early efficacy in treating CDKN2A/MTAP-deleted cancers [2].
In conclusion, Cdkn2a is a key tumor suppressor gene, with its loss significantly contributing to cancer development, especially melanoma. Research on Cdkn2a-related therapeutic strategies offers potential new avenues for precision medicine in melanoma and understanding the treatment of CDKN2A/MTAP-deleted cancers [1,2].
References：
1. Kreuger, Inger Z M, Slieker, Roderick C, van Groningen, Tim, van Doorn, Remco. 2022. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. In The Journal of investigative dermatology, 143, 18-25.e1. doi:10.1016/j.jid.2022.07.016. https://pubmed.ncbi.nlm.nih.gov/36123181/
2. Mulvaney, Kathleen M. . Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers. In Cancer discovery, 13, 2310-2312. doi:10.1158/2159-8290.CD-23-0951. https://pubmed.ncbi.nlm.nih.gov/37909092/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.